These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 34067729)

  • 1. From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas.
    Sun X; Turcan S
    Cells; 2021 May; 10(5):. PubMed ID: 34067729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a three-long non-coding RNA signature for predicting survival of temozolomide-treated isocitrate dehydrogenase mutant low-grade gliomas.
    Li R; Chen W; Mao P; Wang J; Jing J; Sun Q; Wang M; Yu X
    Exp Biol Med (Maywood); 2021 Jan; 246(2):187-196. PubMed ID: 33028081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.
    Lin L; Cai J; Tan Z; Meng X; Li R; Li Y; Jiang C
    Cancer Res Treat; 2021 Apr; 53(2):367-377. PubMed ID: 33070553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telomerase reverse transcriptase promoter mutation- and O
    Gramatzki D; Felsberg J; Hentschel B; Wolter M; Schackert G; Westphal M; Regli L; Thon N; Tatagiba M; Wick W; Schlegel U; Krex D; Matschke J; Roth P; Suresh MP; Kamp MA; Rushing EJ; Pietsch T; von Deimling A; Sabel M; Loeffler M; Weller M; Reifenberger G
    Eur J Cancer; 2021 Apr; 147():84-94. PubMed ID: 33631540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PET With 11C-Methyl-l-Methionine as a Predictor of Consequential Outcomes at the Time of Discontinuing Temozolomide-Adjuvant Chemotherapy in Patients With Residual IDH-Mutant Lower-Grade Glioma.
    Beppu T; Iwaya T; Sato Y; Nomura JI; Terasaki K; Sasaki T; Yamada N; Fujiwara S; Sugai T; Ogasawara K
    Clin Nucl Med; 2022 Jul; 47(7):569-574. PubMed ID: 35452002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV.
    McDuff SGR; Dietrich J; Atkins KM; Oh KS; Loeffler JS; Shih HA
    Cancer Med; 2020 Jan; 9(1):3-11. PubMed ID: 31701682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temozolomide-associated hypermutation in gliomas.
    Choi S; Yu Y; Grimmer MR; Wahl M; Chang SM; Costello JF
    Neuro Oncol; 2018 Sep; 20(10):1300-1309. PubMed ID: 29452419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glutamate Is a Noninvasive Metabolic Biomarker of IDH1-Mutant Glioma Response to Temozolomide Treatment.
    Subramani E; Radoul M; Najac C; Batsios G; Molloy AR; Hong D; Gillespie AM; Santos RD; Viswanath P; Costello JF; Pieper RO; Ronen SM
    Cancer Res; 2020 Nov; 80(22):5098-5108. PubMed ID: 32958546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
    Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas.
    Yu Y; Villanueva-Meyer J; Grimmer MR; Hilz S; Solomon DA; Choi S; Wahl M; Mazor T; Hong C; Shai A; Phillips JJ; Wainer BH; McDermott M; Haas-Kogan D; Taylor JW; Butowski N; Clarke JL; Berger MS; Molinaro AM; Chang SM; Costello JF; Oberheim Bush NA
    Neuro Oncol; 2021 Nov; 23(11):1872-1884. PubMed ID: 33823014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low MGMT digital expression is associated with a better outcome of IDH1 wildtype glioblastomas treated with temozolomide.
    Gomes I; Moreno DA; Dos Reis MB; da Silva LS; Leal LF; Gonçalves GM; Pereira CA; Oliveira MA; de Medeiros Matsushita M; Reis RM
    J Neurooncol; 2021 Jan; 151(2):135-144. PubMed ID: 33400009
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Wu L; Bernal GM; Cahill KE; Pytel P; Fitzpatrick CA; Mashek H; Weichselbaum RR; Yamini B
    Sci Transl Med; 2018 Jul; 10(448):. PubMed ID: 29973405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene expression profiling predicts response to temozolomide in malignant gliomas.
    Yoshino A; Ogino A; Yachi K; Ohta T; Fukushima T; Watanabe T; Katayama Y; Okamoto Y; Naruse N; Sano E; Tsumoto K
    Int J Oncol; 2010 Jun; 36(6):1367-77. PubMed ID: 20428759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Malignant Transformation of Molecularly Classified Adult Low-Grade Glioma.
    Tom MC; Park DYJ; Yang K; Leyrer CM; Wei W; Jia X; Varra V; Yu JS; Chao ST; Balagamwala EH; Suh JH; Vogelbaum MA; Barnett GH; Prayson RA; Stevens GHJ; Peereboom DM; Ahluwalia MS; Murphy ES
    Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1106-1112. PubMed ID: 31461674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ATRX/EZH2 complex epigenetically regulates FADD/PARP1 axis, contributing to TMZ resistance in glioma.
    Han B; Meng X; Wu P; Li Z; Li S; Zhang Y; Zha C; Ye Q; Jiang C; Cai J; Jiang T
    Theranostics; 2020; 10(7):3351-3365. PubMed ID: 32194873
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of IFN-beta on human glioma cell lines with temozolomide resistance.
    Yoshino A; Ogino A; Yachi K; Ohta T; Fukushima T; Watanabe T; Katayama Y; Okamoto Y; Naruse N; Sano E
    Int J Oncol; 2009 Jul; 35(1):139-48. PubMed ID: 19513561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination Olaparib and Temozolomide for the Treatment of Glioma: A Retrospective Case Series.
    Schaff LR; Kushnirsky M; Lin AL; Nandakumar S; Grommes C; Miller AM; Gavrilovic IT; Nolan C; Pentsova E; Mellinghoff IK; Kaley TJ
    Neurology; 2022 Oct; 99(17):750-755. PubMed ID: 35948444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive Analysis Reveals a 4-Gene Signature in Predicting Response to Temozolomide in Low-Grade Glioma Patients.
    Wang Q; He Z; Chen Y
    Cancer Control; 2019; 26(1):1073274819855118. PubMed ID: 31167546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lucanthone, a Potential PPT1 Inhibitor, Perturbs Stemness, Reduces Tumor Microtube Formation, and Slows the Growth of Temozolomide-Resistant Gliomas In Vivo.
    Radin DP; Shifman S; Outhwaite IR; Sharma A; Bases R; Seeliger MA; Tsirka SE
    J Pharmacol Exp Ther; 2024 Mar; 389(1):51-60. PubMed ID: 38296645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study.
    Boccard SG; Marand SV; Geraci S; Pycroft L; Berger FR; Pelletier LA
    Oncotarget; 2015 Oct; 6(30):29456-68. PubMed ID: 26336131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.